Contact Information: CONTACT: Joseph K. Belanoff, M.D. Chief Executive Officer Corcept Therapeutics 650-327-3270 Email Contact www.corcept.com
Nasdaq Panel Grants Corcept Therapeutics' Request for Listing on the Nasdaq Capital Market
| Source: Corcept Therapeutics
MENLO PARK, CA -- (MARKET WIRE) -- April 4, 2007 -- Corcept Therapeutics Incorporated (NASDAQ : CORT ) announced today that a Nasdaq Listing Qualifications Panel has
granted the company's request to be listed on the Nasdaq Capital Market,
effective with the market opening on Monday, April 9, 2007. By transferring
from the Nasdaq Global Market to the Nasdaq Capital Market, Corcept
satisfies all listing requirements. The Company's trading symbol will
remain CORT.
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in
the development of drugs for the treatment of severe psychiatric and
metabolic diseases. Corcept's lead product, CORLUX®, is currently in
Phase III clinical trials for the treatment of the psychotic features of
PMD. The drug is administered orally to PMD patients once per day for
seven days. CORLUX, a potent GR-II antagonist, appears to mitigate the
effects of the elevated and abnormal release patterns of cortisol seen in
PMD. The Company is also conducting a proof-of-concept study evaluating
the ability of CORLUX to mitigate weight gain associated with the use of
olanzapine. For additional information about the company, please visit
www.corcept.com.
Statements made in this news release, other than statements of historical
fact, are forward-looking statements. Forward-looking statements are
subject to a number of known and unknown risks and uncertainties that might
cause actual results to differ materially from those expressed or implied
by such statements. Examples of such forward-looking statements include
statements regarding the pending listing of Corcept common stock on the
NASDAQ Capital Market. These and other risk factors are set forth in the
Company's SEC filings, all of which are available from our website
(www.corcept.com) or from the SEC's website (www.sec.gov). We disclaim any
intention or duty to update any forward-looking statement made in this news
release.